Clinical significance of serum vascular endothelial growth factor and interleukin-6 in multiple myeloma

Journal of Central South University (Medical Sciences)

Volumn 30, Issue 1, 2005, Pages 68-71

  Shen, Jian Kai ^a   Dong, Li Hua ^a   Qi, Hui ^a   Zhang, Guang Sen ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Interleukin 6; Multiple myeloma; Vascular endothelial growth factor

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALCIUM; CHROMIUM; INTERLEUKIN 6; VASCULOTROPIN;

ARTICLE; BLOOD COMPONENT; BONE LESION; BONE METASTASIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SOLID TUMOR;

ADULT; AGED; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33746601855     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis[J]. N Eng J Med, 1995, 333(26): 1757-1763.
2. Frassanito MA, Cusmai A, Lodice G, et al. Interleukin-6 production and highly malignant multiple myeloma; relation with resistance to drug-induced apoptosis [J]. Blond, 2001, 97(2): 483-489.
3. Spets H, Stromberg T, Georgii-Hemming P, et al. Expression of the bcl-2 family of pro- and anti-apoptosis genes in multiple myeloma and normal plasma cells: regulation during interleukin-6 (IL-6)-induced growth and survival[J]. Eur J Haematol, 2002, 69(2): 76-89.
4. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma[J]. Blood, 2000, 95(11): 2630-2636.
5. Alexandrakis MG, Passam FH, Sfiridaki A, et al. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity[J]. Am J Hematol, 2003, 72(4): 229-233.
6. Moehler TM, Ho AD, Goldschmidt H. Angiogenesis in hematologic malignancies[J]. Crit Rev Oncol Hematol, 2003, 45(3): 227-244.
7. Kumar S, Witzig TE, Timm M, et al. Expression of VEGF and its receptors by myeloma cells [J]. Leukemia, 2003, 17(10): 2025-2031.
8. Turensson I, Abildgard N, Ahlgren T, et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors[J]. Br J Hameatol, 1999, 106(4): 1005-1012.
9. Terpos E, Palermos J, Tsionos K, et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma[J]. Eur J Haematol, 2000, 65(1): 331-336.